- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
- Interventions
- PRT1419
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 8,147
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Barrett's Esophagus
- Interventions
- YF476, YF476 placebo
- Drug
- Lead sponsor
- Trio Medicines Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Overactive Bladder, Fecal Incontinence, Non-obstructive Urinary Retention
- Interventions
- InterStim Micro
- Device
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Jacksonville, Florida • Tampa, Florida • Jeffersonville, Indiana + 13 more
- Conditions
- Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
- Interventions
- ADI-PEG 20 plus modified FOLFOX6
- Drug
- Lead sponsor
- Polaris Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 10
- States / cities
- San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more
- Conditions
- Ulcerative Colitis, FMT, Fecal Microbiota Transplant
- Interventions
- Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation
- Drug · Biological
- Lead sponsor
- Ari M Grinspan
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn's Disease (CD), Ulcerative Colitis (UC)
- Interventions
- Vitamin D3
- Dietary Supplement
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Fresno, California
- Conditions
- Colorectal Neoplasms
- Interventions
- Tepotinib, Cetuximab
- Drug · Biological
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
- Conditions
- Colorectal Cancer
- Interventions
- PainPac
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Gastro Esophageal Reflux
- Interventions
- dexlansoprazole
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Intestinal Pseudo-Obstruction, Manipulation, Osteopathic, Postoperative Care, Postoperative Nausea and Vomiting, Postoperative Complications, Osteopathic Medicine
- Interventions
- Rib raising and lumbar release, Sham procedure
- Procedure
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Not listed
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Colorectal Cancer
- Interventions
- Obinutuzumab, Atezolizumab, Cibisatamab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Santa Monica, California • Stanford, California + 4 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Vonoprazan
- Drug
- Lead sponsor
- Phathom Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Hollywood, Florida + 10 more
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Interventions
- gene mapping
- Genetic
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 0 Years to 120 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 32
- States / cities
- Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
- Conditions
- Stomach Neoplasms, Esophageal Neoplasms
- Interventions
- BMS-833923, Cisplatin, Capecitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Houston, Texas
- Conditions
- Colonic Polyp, Colon Cancer
- Interventions
- Orton Score, Typical Standard of Care
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Esophagitis, Reflux, Esophagitis, Peptic
- Interventions
- Dexlansoprazole MR, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 100
- States / cities
- Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
- Conditions
- Advanced Colorectal Cancer
- Interventions
- DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
- Conditions
- Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
- Interventions
- Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 725 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- panitumumab, Randomization to No Panitumumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Diffuse Large-cell B-cell Lymphoma
- Interventions
- Plamotamab, Tafasitamab, Lenalidomide
- Biological · Drug
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Rectal Cancer
- Interventions
- FOLFOXIRI, FOLFOX regimen, XELOX, IMRT
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Depressive Disorder, Anxiety Disorder, Stress Disorders, Post-Traumatic
- Interventions
- Acceptance and Commitment Therapy
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee